EpiCept to Report First Quarter 2012 Operating and Financial Results on May 9, 2012

TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that it will host a conference call to discuss first quarter 2012
operating and financial results on Wednesday, May 9, 2012 at 9:00 a.m. Eastern
time. The call will follow the release of these financial results earlier in the
day at 12:01 a.m. Eastern time.

To participate in the live call and be able to participate in the question and
answer session, please dial from the U.S. and Canada (877) 809-8594 or from
international locations (706) 758-9407 (please reference access code 78786585)
prior to the start of the conference. The conference call will also be broadcast
live in listen-only mode on the Internet and may be accessed at
www.epicept.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2
F 
www.epicept.com&esheet=50265418&lan=en
-US&anchor=www.epicept.com&index=1&md5=062390199057ae43a48e8c20267e5d07). The
webcast will be archived for 90 days.

A telephone replay of the call will be available for seven days by dialing from
the U.S. and Canada (855) 859-2056 or from international locations (404) 537
-3406 (please reference reservation number 78786585).

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical
products for the treatment of pain and cancer. The Company's pain portfolio
includes AmiKet™, a prescription topical analgesic cream in late-stage clinical
development designed to provide effective long-term relief of pain associated
with peripheral neuropathies. The Company's lead oncology product is Ceplene®,
which has been granted full marketing authorization by the European Commission
for the remission maintenance and prevention of relapse in adult patients with
Acute Myeloid Leukemia (AML) in first remission. The Company has other oncology
drug candidates currently in clinical development that were discovered using in
-house technology and have been shown to act as vascular disruption agents in a
variety of solid tumors.

In January 2012, EpiCept engaged SunTrust Robinson Humphrey to assist the
Company in exploring strategic alternatives to maximize the commercial
opportunity of AmiKet™ for the treatment of CIPN following taxane-based therapy.
The engagement is focused on the identification and implementation of a strategy
designed to optimize AmiKet’s value for the Company’s stockholders, which
includes the evaluation of potential transactions involving the sale of the
Company.

Forward-Looking Statements

This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such forward
-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that we will not be able to find a partner to help conduct the
Phase III trials for AmiKet™ on attractive terms, a timely basis or at all, the
risk that Ceplene®will not receive regulatory approval or marketing
authorization in the United States or Canada, the risk that Ceplene® will not
achieve significant commercial success, the risk that any required post-approval
clinical study for Ceplene®will not be successful, the risk that we will not be
able to maintain our final regulatory approval or marketing authorization for
Ceplene®, the risk that Azixa™ will not receive regulatory approval or achieve
significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myrexis, the risk that clinical
trials for AmiKet™ or crolibulinTMwill not be successful, the risk that AmiKet™
or crolibulinTMwill not receive regulatory approval or achieve significant
commercial success, the risk that the development of our EP1013 product
candidate will not be successful, the risk that our other product candidates
that appeared promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later-stage clinical trials, the risk
that we will not obtain approval to market any of our product candidates, the
risks associated with the adequacy of our existing cash resources and our
ability to continue as a going concern, the risks associated with our ability to
continue to meet our obligations under our existing debt agreements, the risks
associated with dependence upon key personnel, the risks associated with
reliance on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product candidates; the
cost, delays and uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our history of
operating losses since our inception; the highly competitive nature of our
business; risks associated with litigation; and risks associated with our
ability to protect our intellectual property. These factors and other material
risks are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in our filings which are available at
www.sec.gov (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
sec.gov&esheet=50265418&lan=en
-US&anchor=www.sec.gov&index=2&md5=0818caa779af7100b1d0ae73e73784f1) or at
www.epicept.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2
F 
www.epicept.com&esheet=50265418&lan=en
-US&anchor=www.epicept.com&index=3&md5=64053abb1f27fcbdc970f913d84c3ed7). You
are cautioned not to place undue reliance on any forward-looking statements, any
of which could turn out to be wrong due to inaccurate assumptions, unknown risks
or uncertainties or other risk factors.

*Azixa is a registered trademark of Myrexis, Inc.

EPCT-GEN
Contacts

EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com